HOME >> BIOLOGY >> NEWS
Inflammation and drugs to control this activity studied in a variety of tumors sites

WASHINGTON, D.C. - Inflammation cuts both ways. When invaded by an infectious agent, for example, the body calls on the forces of inflammation to fight and defeat the intruder. But when the biochemical processes of the immune system are either misdirected or chronically turned on, inflammation can lead to adversity, including some forms of cancer. For this reason, scientists are closely studying the link between inflammatory processes and tumor formation, while others are investigating anti-inflammatory drugs as a means to prevent and treat cancer, as seen by studies presented today at the 97th Annual Meeting of the American Association for Cancer Research.

Antihistamine and Anti-inflammatory Drug Use Associated Differently for High-Grade Versus Low-Grade Gliomas: Abstract No. 486

Individuals who used antihistamines regularly for a six-month period or longer have nearly a three-fold greater risk of developing mid-grade brain tumors, and a two-fold risk of having low-grade tumors. Using anti-inflammatory medications helped protect against developing a deadly brain tumor called glioblastoma.

The researchers, led by Michael Scheurer, Ph.D., postdoctoral fellow in Cancer Prevention and Melissa Bondy, Ph.D., professor of Epidemiology, both at The University of Texas M. D. Anderson Cancer Center in Houston, cautioned that they are not implying that use of antihistamines causes brain tumors, but rather that these medications may be part of a complex milieu of factors that contribute to their development.

Scheurer and Bondy used combined data from two studies: the Harris County Adult Glioma Study and the Bay Area Adult Glioma Study, led by Margaret Wrensch, Ph.D. at the University of California, San Francisco. As part of the studies, participants were asked about their use of antihistamines and anti-inflammatory drugs.

They compared antihistamine and anti-inflammatory drug use in 830 brain tumor cases and 831 controls m
'"/>

Contact: Warren R. Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
4-Apr-2006


Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. Inflammation may cause preterm labor and fetal deaths
2. Inflammation is at the origin and progression of diseases such as diabetes or cancer
3. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
4. Inflammation markers identify fatigue in breast cancer survivors
5. MIT model could predict cells response to drugs
6. New target for HIV/AIDS drugs and vaccine discovered
7. Modified mushrooms may yield human drugs
8. UGR researchers design an alternative to blood test to detect drugs in the body
9. Could fungal collection hold the key to new life-saving drugs?
10. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
11. Scientists develop new drugs to fight colon and breast cancer more effectively

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/18/2019)... ... March 18, 2019 , ... uBiome, ... industry and the third highest quality portfolio following Seres Health and Nestle, as ... Christian Moser, and Theodor Myfleler. uBiome executives Dr. Jessica Richman, PhD, co-founder and ...
(Date:3/14/2019)... , ... March 13, 2019 , ... Bode Technology (Bode), a leading provider ... on more than 100,000 sexual assault kits. As thousands of untested kits are identified ... sexual assault kit backlogs . Bode has tested more than 50,000 kits in the ...
(Date:3/12/2019)... SANTA CLARA, Calif. (PRWEB) , ... March 12, ... ... world leader in strong multi-factor authentication and combined technology all-in-one smart cards, announced ... combined with FIDO strong authentication: the Fingerprint Biometric and Dynamic CVV Payment cards. ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... WHITEHOUSE, N.J. (PRWEB) , ... March 19, 2019 , ... ... and is a great opportunity to see the most cutting-edge cancer research. The Visikol ... work with 3D cell culture assays as well as their digital ...
(Date:3/19/2019)... ... ... will review strategies for data management in modular and adaptive clinical trials. , Participants will:, ... 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... reducing risk and impact on trial success, trial teams, and trial execution , ...
(Date:3/15/2019)... (PRWEB) , ... March 15, ... ... of 100% equity in American Process Inc. and affiliate companies including AVAPCO ... Biorefinery in Alpena Michigan, the Thomaston Biorefinery and R&D center in Thomaston, ...
(Date:3/14/2019)... DESERT, Calif. (PRWEB) , ... March 14, 2019 ... ... issued a press release announcing that its Canadian partner, the Eye Machine Canada ... Canada, using Nova Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD). , ...
Breaking Biology Technology:
Cached News: